North America
Kyowa Kirin Will Present New Rocatinlimab Phase 2b Data in Atopic Dermatitis at the American Academy of Dermatology Annual Meeting 2023
BEDMINSTER, N.J. and TOKYO, March 17, 2023 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announces that data from the Phase 2b study of rocatinlimab (KHK4083/AMG 451), an investigational product in patients with moderate-to-severe atopic dermatitis, will be presented in two posters at the upcoming American Academy of Dermatology (AAD) 2023 Annual Meeting to be held March 17-22, 2023, in New Orleans, Louisiana, USA.
Atopic dermatitis (AD), a chronic, heterogeneous, inflammatory disease characterized by skin redness, pruritus, and pain, is driven by skin barrier disruption and T cell-dependent inflammatory pathways; the relative contribution of different inflammatory pathways in driving disease can vary across populations and within individuals over time.
Often beginning in childhood, AD affects 15-20% of children and up to 10% of adults, making it the 15th most common nonfatal disease.1 AD is prevalent in countries globally, with approximately 1 in 3 p
17 March 2023